Trials / Completed
CompletedNCT00133848
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 210 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 9 Months
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB-275833 ointment, 1% |
Timeline
- Start date
- 2005-04-01
- Completion
- 2006-01-01
- First posted
- 2005-08-24
- Last updated
- 2016-09-23
Locations
22 sites across 5 countries: India, Italy, Mexico, Netherlands, Peru
Source: ClinicalTrials.gov record NCT00133848. Inclusion in this directory is not an endorsement.